Amarin Corp plc (AMRN) Misses Q2 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall St rebounds, but yield surge sets stage for weekly losses
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Supermicro probe finds no senior management link to export violations
- Hertz Global amends voting agreement with CK Amarillo after lawsuit
- SpaceX shares fall as second lockup period ends
Amarin Reports Second Quarter 2015 Financial Results and Provides Update on Operations
August 6, 2015 4:02 PM EDTBEDMINSTER, NJ and DUBLIN, IRELAND -- (Marketwired) -- 08/06/15 -- Amarin Corporation plc (NASDAQ: AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, today announced financial results for the three and six months ended June 30, 2015, and provided an update on company operations.
Key Amarin achievements since March 31, 2015 include:
R&D progress: REDUCE-IT, the first prospective cardiovascular outcomes study to evaluate the effect of treating patients who despite statin therapy have elevated triglyceride levels... MorePoseida Therapeutics, Inc., Expands Board of Directors
August 5, 2015 4:27 PM EDTSAN DIEGO, Aug. 5, 2015 (GLOBE NEWSWIRE) -- Poseida Therapeutics, Inc. (Poseida), a privately-held human therapeutics spinout of Transposagen Biopharmaceuticals, Inc. (Transposagen), announces the appointment of Lars Ekman, M.D., Ph.D. and Nishan de Silva, M.D. to the Company's Board of Directors. Dr. Ekman joins the Board as the Company's Chairman, and Dr. de Silva is appointed President.
"We are pleased to welcome Dr. Ekman and Dr. de Silva to our Board of Directors. Dr. Ekman brings a wealth of valuable drug development and industry experience to Poseida through his prior leadership roles in R&D at several global... More
Poseida Therapeutics, Inc., Expands Board of Directors
August 5, 2015 4:27 PM EDTSAN DIEGO, Aug. 5, 2015 (GLOBE NEWSWIRE) -- Poseida Therapeutics, Inc. (Poseida), a privately-held human therapeutics spinout of Transposagen Biopharmaceuticals, Inc. (Transposagen), announces the appointment of Lars Ekman, M.D., Ph.D. and Nishan de Silva, M.D. to the Company's Board of Directors. Dr. Ekman joins the Board as the Company's Chairman, and Dr. de Silva is appointed President.
"We are pleased to welcome Dr. Ekman and Dr. de Silva to our Board of Directors. Dr. Ekman brings a wealth of valuable drug development and industry experience to Poseida through his prior leadership roles in R&D at several global... More
